GlassScriptPhysician profile
Yazen Assaf
NPI 1962938118
$5,202.73
in general payments reported to CMS, 2019-2025
12 companies · $2,237 in 2025
The $2,237 reported for 2025 was more than what 83% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $32.95 · 2024: $2,932 · 2025: $2,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,817 · Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,816.53 |
| Food and Beverage | $886.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,741.36 | 2024-2025 | |
| Davol INC. | $1,004.40 | 2024-2025 | Phasix Mesh, Arista |
| Medtronic, INC. | $136.03 | 2024 | Signia, Ligasure |
| Novo Nordisk INC | $58.81 | 2023-2025 | Wegovy |
| Kerecis Limited | $56.96 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Lilly USA, LLC | $41.99 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Becton, Dickinson and Company | $40.69 | 2024 | Phasix Mesh |
| Ethicon US, LLC | $33.45 | 2025 | Echelon; Endopath |
| Abbvie INC. | $33.28 | 2025 | |
| Abbott Laboratories | $24.83 | 2024 | Cardiomems |
| Aimmune Therapeutics, INC. | $16.72 | 2024 | |
| Teleflex LLC | $14.21 | 2024 | Deknatel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yazen Assaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.